{"doi":"10.1093/jac/dkr151","title":"Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration","abstract":null,"journal":"Journal of Antimicrobial Chemotherapy","year":2011,"id":597054,"datarank":0.4887144807032224,"base_score":3.258096538021482,"endowment":3.258096538021482,"self_citation_contribution":0.4887144807032224,"citation_network_contribution":0.0,"self_endowment_contribution":0.4887144807032224,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":25,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1529361,"name":"T. Buclin","orcid":null,"position":1,"is_corresponding":false},{"id":1529362,"name":"C. Franc","orcid":null,"position":2,"is_corresponding":false},{"id":1529363,"name":"S. Colombo","orcid":null,"position":3,"is_corresponding":false},{"id":1529364,"name":"S. Cruchon","orcid":null,"position":4,"is_corresponding":false},{"id":1529365,"name":"N. Guignard","orcid":null,"position":5,"is_corresponding":false},{"id":1529366,"name":"J. Biollaz","orcid":null,"position":6,"is_corresponding":false},{"id":900270,"name":"A. Telenti","orcid":null,"position":7,"is_corresponding":false},{"id":1529367,"name":"L. A. Decosterd","orcid":null,"position":8,"is_corresponding":false},{"id":859886,"name":"M. Cavassini","orcid":null,"position":9,"is_corresponding":false},{"id":1529360,"name":"A. Fayet Mello","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration","abstract":"OBJECTIVES: The site of pharmacological activity of raltegravir is intracellular. Our aim was to determine the extent of raltegravir cellular penetration and whether raltegravir total plasma concentration (C(tot)) predicts cellular concentration (C(cell)). METHODS: Open-label, prospective, pharmacokinetic study on HIV-infected patients on a stable raltegravir-containing regimen. Plasma and peripheral blood mononuclear cells were simultaneously collected during a 12 h dosing interval after drug intake. C(tot) and C(cell) of raltegravir, darunavir, etravirine, maraviroc and ritonavir were measured by liquid chromatography coupled to tandem mass spectrometry after protein precipitation. Longitudinal mixed effects analysis was applied to the C(cell)/C(tot) ratio. RESULTS: Ten HIV-infected patients were included. The geometric mean (GM) raltegravir total plasma maximum concentration (C(max)), minimum concentration (C(min)) and area under the time-concentration curve from 0-12 h (AUC(0-12)) were 1068 ng/mL, 51.1 ng/mL and 4171 ng·h/mL, respectively. GM raltegravir cellular C(max), C(min) and AUC(0-12) were 27.5 ng/mL, 2.9 ng/mL and 165 ng·h/mL, respectively. Raltegravir C(cell) corresponded to 5.3% of C(tot) measured simultaneously. Both concentrations fluctuate in parallel, with C(cell)/C(tot) ratios remaining fairly constant for each patient without a significant time-related trend over the dosing interval. The AUC(cell)/AUC(tot) GM ratios for raltegravir, darunavir and etravirine were 0.039, 0.14 and 1.55, respectively. CONCLUSIONS: Raltegravir C(cell) correlated with C(tot) (r = 0.86). Raltegravir penetration into cells is low overall (∼5% of plasma levels), with distinct raltegravir cellular penetration varying by as much as 15-fold between patients. The importance of this finding in the context of development of resistance to integrase inhibitors needs to be further investigated.","is_dataset_classified":null,"base_score":3.258096538021482,"endowment":3.258096538021482,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"21508009","pmcid":null,"openalex_id":"https://openalex.org/W2110945650","authors":[],"funders":[{"funder_name":"Swiss National Science Foundation","grant_id":"124943","title":"Pharmacocinétique de population, pharmacogénétique, et profils métaboliques de la thérapie anti-HIV"}],"total_grants":1,"fwci":2.4445,"citation_percentile":0.88503766,"influential_citations":0,"citation_trend":[{"year":2012,"count":4},{"year":2013,"count":5},{"year":2014,"count":4},{"year":2015,"count":1},{"year":2016,"count":3},{"year":2017,"count":1},{"year":2019,"count":1},{"year":2020,"count":1},{"year":2022,"count":2}],"oa_status":"green","license":"other-oa","oa_locations":[{"url":"https://serval.unil.ch/notice/serval:BIB_525AF0812F4D","host_type":"repository"},{"url":"https://serval.unil.ch/notice/serval:BIB_525AF0812F4D","host_type":"repository"},{"url":"http://academic.oup.com/jac/article-pdf/66/7/1573/2345683/dkr151.pdf","host_type":"publisher"},{"url":"https://doi.org/10.1093/jac/dkr151","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/21508009","host_type":"repository"},{"url":"https://iris.unil.ch/handle/iris/86756","host_type":"repository"},{"url":"http://jac.oxfordjournals.org/cgi/content/short/dkr151v1","host_type":"repository"},{"url":"https://iris.unil.ch/bitstreams/e89a3753-b5b4-41b3-923a-9f7d9a0d2208/download","host_type":"repository"},{"url":"https://academic.oup.com/jac/article-pdf/66/7/1573/2345683/dkr151.pdf","host_type":""},{"url":"https://dx.doi.org/10.1093/jac/dkr151","host_type":""},{"url":"https://sonar.ch/global/documents/78487","host_type":""},{"url":"http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_525AF0812F4D9","host_type":""},{"url":"https://serval.unil.ch/resource/serval:BIB_525AF0812F4D.P001/REF.pdf","host_type":""},{"url":"http://dx.doi.org/10.1093/jac/dkr151","host_type":""}],"fields_of_study":["HIV/AIDS drug development and treatment","HIV Research and Treatment","HIV/AIDS Research and Interventions","03 medical and health sciences","0302 clinical medicine"],"mesh_terms":["Raltegravir Potassium","Adult","Aged","Chromatography, Liquid","Cytoplasm","Female","Humans","Leukocytes, Mononuclear","Male","Middle Aged","Plasma","Prospective Studies","Pyrrolidinones","Mass Spectrometry","HIV Infections","Anti-HIV Agents"],"keywords":["Raltegravir","Darunavir","Maraviroc","Etravirine","Pharmacokinetics","Pharmacology","Chemistry","Integrase inhibitor","Ritonavir","Chromatography","Viral load","Medicine","Human immunodeficiency virus (HIV)","Immunology","Antiretroviral therapy","Adult","Male","Cytoplasm","Anti-HIV Agents","HIV Infections","Middle Aged","Mass Spectrometry","Pyrrolidinones","Plasma","Raltegravir Potassium","Leukocytes, Mononuclear","Humans","Female","Prospective Studies","Aged","Chromatography, Liquid"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"},{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-28T12:05:20.329744Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}